EGFR tyrosine kinase
EGFR-tyrosine kinase inhibitors, such as Tarceva (erlotinib), or Irressa (gefitinib), can stop disease progression for "EGFR positive" lung adenocarcinoma. But once the cancer acquire further mutation such as T790->M, these inhibitors are no longer effective. To overcome resistance, 2nd generation TKi are in NIH clinical trial stage - example, BIBW 2992 is suppose to be effective regardless of further mutation of the tk gene.
About 10% asian lung cancer patients are "EGFK positive".
EML4-ALK
The experimental drug crizotinib is effective against majority of "EML4-ALK fusion positive" lung cancer (both adenocarcinoma and squamous cell cancer), and it is in phase 2 and phase 3 NIH clinical trials right now.
About 5-10% of lung cancers belong to EML4-ALK fusion type. I predict Manabu Soda will receive Nobel prize in medicine.
EGFR-tyrosine kinase inhibitors, such as Tarceva (erlotinib), or Irressa (gefitinib), can stop disease progression for "EGFR positive" lung adenocarcinoma. But once the cancer acquire further mutation such as T790->M, these inhibitors are no longer effective. To overcome resistance, 2nd generation TKi are in NIH clinical trial stage - example, BIBW 2992 is suppose to be effective regardless of further mutation of the tk gene.
About 10% asian lung cancer patients are "EGFK positive".
EML4-ALK
The experimental drug crizotinib is effective against majority of "EML4-ALK fusion positive" lung cancer (both adenocarcinoma and squamous cell cancer), and it is in phase 2 and phase 3 NIH clinical trials right now.
About 5-10% of lung cancers belong to EML4-ALK fusion type. I predict Manabu Soda will receive Nobel prize in medicine.
选择“Disable on www.wenxuecity.com”
选择“don't run on pages on this domain”
